Last €68.97 EUR
Change Today -0.28 / -0.40%
Volume 240.9K
UCB On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
OTC US
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UCB) Snapshot

Open
€69.61
Previous Close
€69.25
Day High
€69.86
Day Low
€68.79
52 Week High
08/29/14 - €75.62
52 Week Low
02/26/14 - €50.11
Market Cap
13.4B
Average Volume 10 Days
268.4K
EPS TTM
€1.34
Shares Outstanding
194.5M
EX-Date
04/29/14
P/E TM
51.5x
Dividend
€1.04
Dividend Yield
1.51%
Current Stock Chart for UCB SA (UCB)

Related News

No related news articles were found.

ucb sa (UCB) Related Businessweek News

No Related Businessweek News Found

ucb sa (UCB) Details

UCB S.A., a global biopharmaceutical company, focuses on central nervous system disorders and immunology diseases. The company’s core products include Cimzia for inflammatory arthritis indications and Crohn’s disease; Vimpat for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for cognitive disorders; and Omeprazole for hyperacidity diseases. The company is also developing Vimpat for epilepsy partial-onset seizures (POS)/monotherapy, epilepsy POS/pediatric adjunctive therapy, and epilepsy primary generalized tonic clonic seizures/adjunctive therapy; brivaracetam as adjunctive therapy for epilepsy; and tozadenant for Parkinson’s disease. Its products under development also comprise Cimzia for axial spondyloarthritis and juvenile idiopathic arthritis; epratuzumab for systemic lupus erythematosus; romosozumab for post-menopausal osteoporosis; CDP7657 for systemic lupus erythematosus; and UCB4940, UCB5857, and UCB7665 for immunological diseases. The company has collaborations with ConfometRx, Five Prime Therapeutics, CRELUX and 4SC Discovery, The Lieber Institute For Brain Development, Neuropore Therapies Inc., and Biogen Idec. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,224 Employees
Last Reported Date: 02/28/14
Founded in 1928

ucb sa (UCB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ucb sa (UCB) Key Developments

UCB SA Announces Executive Changes

UCB SA has named Jean-Christophe Tellier to succeed Roch Doliveux as the company's new CEO. He is also Chairman of UCB's Executive Committee and member of the Board of Directors. Roch Doliveux stepped down on 31 December 2014 after leading UCB for the last 10 years. Jean-Christophe Tellier joined the company in 2011 and was instrumental in establishing the company's current strategy.

Neuropore Therapies Inc. and UCB Enter into World-Wide Collaboration and Agreement

Neuropore Therapies Inc. and UCB announced that they have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson's disease and related disorders. This includes NPT200-11, Neuropore's novel small molecule that targets pathogenic alpha-synuclein which is currently in preclinical development and is expected to enter clinical Phase 1 in 2015. Under the terms of the agreement, UCB will receive the world-wide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first Phase 1 study to be initiated in 2015. UCB will lead all further clinical development, regulatory activities and commercialization. Neuropore will receive an initial upfront payment of USD 20 million and is entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of USD 460 million, in addition to royalties on net sales. Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. There are an estimated seven to ten million patients with PD worldwide. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms. By stabilizing conformations of alpha-synuclein that are then incapable of assembling into toxic pore-like oligomers in cell membranes, NPT200-11 blocks the pathological protein misfolding, aggregation and deposition that contribute to synaptic dysfunction and cell death in PD and related disorders. NPT200-11 is orally bioavailable, has promising drug-like properties and, has shown robust beneficial actions on multiple endpoints in animal models.

UCB S.A. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 09:30 AM

UCB S.A. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jean-Christophe Tellier, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €68.97 EUR -0.28

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $79.61 USD -2.03
Grifols SA €37.25 EUR +0.01
Hospira Inc $63.43 USD -1.35
Sigma-Aldrich Corp $137.52 USD -0.13
Valspar Corp/The $83.43 USD -0.35
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 37.6x
Price/Sales 3.1x
Price/Book 2.3x
Price/Cash Flow 38.8x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.